Astellas/Cardiome’s Kynapid “Approvable”
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants more safety data on IV vernakalant.
You may also be interested in...
A Year Of Reconsiderations For US FDA Advisory Committees
Correvio’s anti-arrhythmic vernakalant is returning to an advisory committee a dozen years after its first review, continuing a recent pattern of return visits for applications – and 12 years isn’t even close to the longest long back for US FDA panel in 2019.
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Merck & Co. is acquiring North American rights to intravenous vernakalant from Astellas Pharma's U.S. subsidiary, Merck announced on July 26. The agreement will consolidate its interest in the cardiovascular drug to include worldwide rights to both the IV and oral formulations
Merck Consolidates All Rights To Vernakalant By Assuming North American Rights From Astellas
Already holding worldwide rights to the oral formulation and rest-of-world rights to intravenous vernakalant, Merck will partner with Cardiome Pharma to obtain FDA approval of IV vernakalant.